The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego

Similar documents
Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis

Mechanisms of hepatic fibrogenesis in chronic liver disease

NASH Bench to Bedside

A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se

18s AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA. 36b4 GTTCTTGCCCATCAGCACC AGATGCAGCAGATCCGCAT. Acc1 AGCAGATCCGCAGCTTG ACCTCTGCTCGCTGAGTGC

The role of Hepatitis C Virus in hepatocarcinogenesis

Supplementary Figure 1

Virchow s Hypothesis lymphorecticular infiltration of cancer reflected the origin of cancer at sites of inflammation

Forward-looking Statements

Alcoholic hepatitis is a drug-induced disorder

Reviewers' comments: Reviewer #1 (Remarks to the Author):

Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis

Trehalose, sucrose and raffinose are novel activators of autophagy in human. keratinocytes through an mtor-independent pathway

Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with

Molecular mechanisms of Fibrosis: Targets of Therapy. John P Iredale University of Edinburgh, UK

Disclosures. Outline. Extracellular Vesicles in Fatty Liver Disease. From Contributors to disease pathogenesis to novel biomarkers

The liver in poisoning: what can we learn from animal models?

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

Defective Hepatic Autophagy in Obesity Promotes ER Stress and Causes Insulin Resistance

Identified proteins interacting with TMBIM1 by mass spectrometry

Supplementary Figure 1. Expression of CUGBP1 in non-parenchymal liver cells treated with TGF-β

Supplemental Information. Increased 4E-BP1 Expression Protects. against Diet-Induced Obesity and Insulin. Resistance in Male Mice

Nonalcoholic fatty liver disease (NAFLD), the

Cell Quality Control. Peter Takizawa Department of Cell Biology

Hypothalamic Autophagy and Regulation of Energy Balance

Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsrna-induced retinal degeneration

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Supplementary Figure 1.

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC

Conflicts of Interest in the last 12 months

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

A Central Role of MG53 in Metabolic Syndrome. and Type-2 Diabetes

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

shehab Moh Tarek ... ManarHajeer

SUPPLEMENTARY INFORMATION

Liposome Mediated Delivery of sirna to Hepatic Stellate Cells Alfica Sehgal, Mohammad Zafari, Boris Klebanov, Greg Hinkle, Satya Kuchimanchi, Sarfraz

RAW264.7 cells stably expressing control shrna (Con) or GSK3b-specific shrna (sh-

Supplementary Figure 1

Intracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation

Connective Tissue Response in IBD

Cheng Liu 1, Xia Yuan 2, Le Tao 3, Zhuoan Cheng 1, Xiuqin Dai 1, Xia Sheng 4 and Dongying Xue 3*

D2 inhibits TLR2- initiated 12p40 transcription (-) TLR2 PGN MDP. MyD88 IRAK ECSIT TRAF6 NIK. Smallest unit of PGN muramyl dipeptide IKK.

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Figure S1. IRF5 mrna expression is not expressed modulated by steatosis grade in

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease.

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

Supplementary Information. Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis.

Fibrosis is a highly conserved response to hepatic

Innate Immune Consequences of Hepatocyte Injury. Katherine J. Brempelis. A dissertation. submitted in partial fulfillment of the

Signaling Through Immune System Receptors (Ch. 7)

LIPOCALIN 2 DEFICIENCY INFLUENCES TRANSFORMING GROWTH FACTOR-β EFFECT ON INFLAMMATION AND EXTRACELLULAR MATRIX REMODELING IN INGUINAL ADIPOCYTES

Principles of Genetics and Molecular Biology

Nonalcoholic steatohepatitis (NASH), characterized

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

How Will New Therapies Affect HCC Development?

Company Overview. September 2018 NASDAQ: MDGL

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Hepatitis C Virus and Cytokine Responses

Introduction: 年 Fas signal-mediated apoptosis. PI3K/Akt

Decoy receptor 3 alleviates hepatic fibrosis through suppressing inflammation activated by NF-κB signaling pathway

SUPPLEMENTARY INFORMATION

Tbk1-TKO! DN cells (%)! 15! 10!

NFκB What is it and What s the deal with radicals?

Appendix Table of Contents. 1. Appendix Figure legends S1-S13 and Appendix Table S1 and S2. 2. Appendix Figures S1-S13

Nonalcoholic fatty liver disease (NAFLD) is one of

Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice

Supplementary Figures

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

SUPPLEMENTARY INFORMATION

Sestrin2-mediated signaling in autophagy induction and oxidative metabolism

Insulin Resistance. Biol 405 Molecular Medicine

1. Activated receptor tyrosine kinases (RTKs) phosphorylates themselves

The Future Outlook to DILI Research From The Perspective of China

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9

Supplementary Figure 1: Additional metabolic parameters of obesity mouse models and controls. (a) Body weight, (b) blood glucose and (c) insulin

Gene Polymorphisms and Carbohydrate Diets. James M. Ntambi Ph.D

Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk

Supplementary Information File

Improving the Lives of Patients with Liver Diseases

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27

Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice

Master class Biomolecular Sciences Molecular Cell Biology.

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Chapter 3. Toxicity and the Factors That Modify Toxic Responses

AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

AAV-TBGp-Cre treatment resulted in hepatocyte-specific GH receptor gene recombination

Title: Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events

1.5 ASK1KO fed. fasted 16 hrs w/o water. Fed. 4th. 4th WT ASK1KO N=29, 11(WT), ,5(ASK1KO) ASK1KO ASK1KO **** Time [h]

Supporting Information. Supporting Tables. S-Table 1 Primer pairs for RT-PCR. Product size. Gene Primer pairs

Is there a common mechanism of DILI, do we need to know?

Fang et al. NMuMG. PyVmT unstained Anti-CCR2-PE MDA-MB MCF MCF10A

Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis

Liver fibrosis: Twenty years after. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica Università di Firenze

University of California, San Diego La Jolla CA 92093

ZL ZDF ZDF + E2 *** Visceral (g) ZDF

Antibodies for Unfolded Protein Response

Transcription:

The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease Ekihiro Seki, M.D.,Ph.D. University of California San Diego

- A manufactured chemical. - Does not exist naturally. Carbon tetrachloride (CCl 4 ) - Clear liquid with a sweet odor that smells like chloroform. - Easily vaporizes. - High levels or continuous low dose exposure influence to liver, and cause hepatocyte injury, liver fibrosis and hepatocarcinogenesis. Trichloromethyl radical (Free radical) Lipid peroxidation Hepatotoxicity

Carbon tetrachloride (CCl 4 ) - Has been used for dry-cleaning, solvent, reagent in chemical synthesis, fire extinguisher fluid, and refrigerants. - The use and production of CCl 4 was declined in the mid 197s, but it has been diffusing into air, water and soil. It takes for several years to break down - In air of.1 ppb are common around the world. - In water or soil, ranging from 5 to over 1, ppb at 22% of the Superfund sites. - 47 th and 5 th RANK (27 CERCLA and 211 ATSDR priority lists)

NAFLD Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of liver disease in the United States The prevalence of obesity and diabetes increases 6-7% of obese adults have NAFLD 3-4% of adults in the western world have NAFLD 15-2% of NAFLD patients progress to NASH According to a 28 estimation, NAFLD will be the leading cause for liver transplantation by 22.

Question: Does Fatty liver disease affects the sensitivity to toxin exposure? High fat diet Chronic Industrial Toxin Exposure Fatty Liver?

Activation of Stellate cells in Liver Fibrosis Carbon tetrachloride, HBV, HCV, NASH, Alcohol Cyp2E1 Hepatocyte Death TNF- TGF-? TGF- Activated Stellate cell

The Effect of Fatty Liver in Toxin-induced Liver Fibrosis 8x CCl 4 (.25ul/g BW) or corn oil LFD HFD HFD for 2M HFD for 1M 8x CCl 4 (.25ul/g BW) or corn oil

Serum ALT (U/L) HFD feeding enhances Toxin-induced Liver Injury LFD + Oil HFD + Oil 12 1 8 LFD * HFD * 6 LFD + CCl 4 HFD + CCl 4 4 2 Oil CCl 4 8 x CCl 4 (.25 ul/g BW)

Serum ALT (U/L) Tnf mrna [fold] Ccl2 mrna [fold] HFD feeding enhances Toxin-induced Liver Inflammation LFD HFD LFD HFD 12 * * 3 * 3 * * 1 2.5 25 8 2 2 6 1.5 15 4 1 1 2.5 5 Oil CCl 4 Oil CCl 4 Oil CCl 4 8 x CCl 4 (.25 ul/g BW)

Sirius red staining area (%) HFD feeding enhances Toxin-induced Liver Fibrosis 1 8 6 4 2 LFD HFD * * Oil CCl 4

Col1a1 mrna [fold] Acta2 mrna [fold] Timp1 mrna [fold] Tgfb1 mrna [fold] HFD feeding enhances Toxin-induced Liver Fibrosis LFD HFD 15 1 5 * * * * * * * * Oil CCl 4 25 2 15 1 5 25 2 15 1 5 Oil CCl 4 Oil CCl 4 Oil CCl 4 6 5 4 3 2 1

What is the Underlying Mechanism of Increased Sensitivity to CCl 4? High fat diet Chronic CCl 4 Exposure Fatty Liver 1. Increased sensitivity to hepatocyte death. 2. Increased capacity to produce cytokines. 3. Increased production of extracellular matrix. 4. Increased production of toxic metabolite from CCl 4.

Serine Rich region TGF- activated kinase 1 (TAK1) TAK1 is a 78-8 kda protein, which is encoded by the MAP3K7 gene. TAK1 is a serine/ threonine kinase, and belong to MAP3K family. Phosphorylation and ubiquitination of TAK1 are important for activation of TAK1 and its downstream molecules. TAK1 interacts with TAB1, TAB2 and TAB3 that regulate TAK1 full activation. TAK1 is activated in the signaling of TNF, IL-1, TLRs and TGF-. TAK1 regulates activation of NF- B, JNK, p38, AMPK and NLK. Catalytic domain P P 1 3 Thr Ser 36 Ser 579 184/187 192 412 P 72 158 178 Lys Lys Thr Ub Ub P TAB1 TAB2/3

TAK1 Regulates NF- B and JNK Pathways, and also Regulates AMPK-Autophagy Pathway TNF TGF Metabolic stress (AMP/ATP, starvation) TAK1 TAK1 NEMO IKK NF- B JNK AP-1 AMPK mtorc1 autophagy Hepatocyte Death Hepatocyte Death

Tak1 mrna [fold] Tak1 mrna [fold] TAK1/ -actin [fold] Hepatic TAK1 expression is decreased in advanced fatty liver disease 1.2 1.8.6.4.2 1.2 1.8.6.4.2 LFD ** LFD 8M-HFD TAK1 β-actin HFD ** WT Ob/Ob TAK1 β-actin 1.2 1.8.6.4.2 1.2 1.8.6.4.2 LFD ** * HFD WT Ob/Ob WT Ob/Ob

Hepatic TAK1 expression is decreased in fatty liver with toxin exposure (2M) (2M)

Does Decreased TAK1 Expression Increase Sensitivity to CCl 4? High fat diet Chronic CCl 4 Exposure TAK1 Does Decreased TAK1 Play a Role? Fatty Liver

Generation of hepatocyte-specific TAK1-deleted mice Alb-Cre-Tg mice Tak1 flox/flox mice X Alb-promoter Cre-recombinase exon1 exon2 exon3 exon4 loxp loxp exon1 exon3 exon4 loxp TAK1 TAK1 Whole liver WT Tak1 HEP Hepatocytes WT Tak1 HEP TAK1 TAK1

Sirius red pos area (%) CCl 4 exposure augmentes liver fibrosis in Tak1 HEP mice WT-oil WT-CCl 4 25 2 15 1 * * Tak1 HEP -oil Tak1 HEP -CCl 4 5 CCl 4 - + - + 12 injections (5-6 month old)

ALT (U/L) Col1a1 mrna [fold] Acta2 mrna [fold] Timp1 mrna [fold] TAK1 deficiency enhanced liver injury and fibrogenic response after chronic exposure to CCl 4 14 12 1 8 6 * 4 2 CCl 4 - + - + * 6 5 4 3 2 1 * 3 2 1 * * CCl 4 - + - + CCl 4 - + - + CCl 4 - + - + 4 3 2 1

Why Does Decreased TAK1 Expression Increase Sensitivity to CCl 4 Exposure? 1.Sensitivity to TNF -induced hepatocyte death 2.Sensitivity to TGF -induced hepatocyte death 3.Autophagy in hepatocytes.

TAK1 -/- hepatocytes lack TNF -induced NF- B activation and are susceptible to cell death CCl 4 exposure inflammation TNF IL-1 TNF TNFR TAK1 NF- B Survival JNK Kupffer cells TGF DAMPs Hepatic stellate cells Caspase-3 Apoptosis Necrosis SMA TIMP1 Collagen Liver fibrosis Hepatocytes (Inokuchi et al 21, PNAS)

number of cell death (%) Caspase-3 activity (RFU/min) TAK1 -/- hepatocytes lack TNF -induced NF- B activation and are susceptible to cell death TNF- (min) NF- B pjnk JNK caspase-3 Cleaved caspase-3 WT 1 3 6 18 36 (Inokuchi et al 21, PNAS) Tak1 HEP 1 3 6 18 36 12 1 8 6 4 2 3 25 2 15 1 5 WT necrosis apoptosis WT ** TNF- - + - + Tak1 HEP ** TNF- - + - + Tak1 HEP

TAK1 -/- hepatocytes augment TGF -mediated Smad2/3 activation and are susceptible to cell death CCl 4 exposure inflammation TNF IL-1 TGF TGFbR TAK1 NF- B JNK Survival Kupffer cells TGF DAMPs Hepatic stellate cells Smad2/3/4 Caspase-3 Apoptosis Necrosis SMA TIMP1 Collagen Liver fibrosis Hepatocytes (Yang et al 213, Gastroenterology)

TUNEL-pos cells/hpf TAK1 -/- hepatocytes augment TGF -mediated Smad2/3 activation and are susceptible to cell death WT Tak1 HEP 3 * ** TGFβ(min) 1 3 6 18 36 1 3 6 18 36 25 psmad2 Smad2 2 15 * * psmad3 1 Smad3 5 Cleaved Caspase3 Caspase3 TGFβ - + - + - + - + 1ng/ml WT Tak1 -/- Smad4 -/- Tak1 -/- Smad4 -/- (Yang et al 213, Gastroenterology)

Autophagy Autophagy is a process to degrade intracellular components (long-lived or aggregated proteins, lipids, and damaged organelles, such as mitochondria) in lysosomes to supply for energy generation for maintaining cellular homeostasis. Cell death, Cancer, Fatty Liver, Type II Diabetes, Innate Immune Systems, Aging, Infectious Disease, Toxin exposure, Fibrosis.

LC3B aggregates/ cell N.D. % LD with AV Fasted Fed WT Autophagy is suppressed in TAK1 HEP mice Tak1 hep Fed Fasted Fed Fasted LC3B IHC Electron Microscope WT Tak1 hep WT Tak1 hep p-s6 p62 LC3B-I LC3B-II -actin Fasted Fed Starvation Hepatocyte Death TAK1 AMPK mtorc1 Autophagy 25 2 15 1 5 WT ** Fed Tak1 hep WT Tak1 hep ** ** 5 * ** 4 3 2 1 Fasted Fed Fasted (Inokuchi-Shimizu et al 214, J Clin Invest)

Ratio (LC3B-GFP-II/I) TAK1 -/- -LC3B GFP WT-LC3B GFP LC3B-GFP (dots/cell) Autophagic LC3B aggregation is suppressed in TAK1 -/- hepatocytes medium starvation 6 ** 5 4 3 2 1 ** WT Tak1 -/- medium WT Tak1 -/- starvation GFP-LC3B-I GFP-LC3B-II p62 -actin WT Tak1 -/- starvation starvation 3 ** 2 1 starvation - + - + WT Tak1 -/-

Starvation-induced AMPK activation is inhibited in TAK1 -/- hepatocytes TAK1 plkb1 WT Tak1 -/- starvation starvation 2h 6h 2h 6h Starvation TAK1 LKB1 pampk AMPK praptor Raptor pulk1 ULK1 -actin P P LKB1 AMPK P P Raptor ULK1 mtor Autophagy mtorc1 LC3B p62

Rapamycin Restores Autophagy in TAK1 -/- Hepatocytes WT Starvation WT TAK1 -/- rapa - + - + TAK1 Tak1 GFP-LC3B-I GFP-LC3B-II p62 ps6 TAK1 -/- P LKB1 AMPK Raptor P P T-S6 -actin (Inokuchi-Shimizu et al 214, J Clin Invest) mtor Autophagy S6K Rapa P S6

TUNEL pos cells (/x1 filed) ALT (U/L) Rapamycin Suppresses Liver Injury in Tak1 HEP mice 6 2 * * 5 4 3 15 1 2 1 5 rapamycin - - + + rapamycin - - + + WT TAK1 HEP WT TAK1 HEP (Inokuchi-Shimizu et al 214, J Clin Invest)

Sirius Red pos Area (%) Rapamycin Suppresses Liver Fibrosis in Tak1 HEP mice Tak1 HEP mice 8 * 6 4 Vehicle rapamycin Injection of 5mg/kgBW rapamycin 2 times/week from 28 to 36 weeks 2 Vehicle rapa (Inokuchi-Shimizu et al 214, J Clin Invest)

The enhancement of toxin-induced liver fibrosis in fatty liver disease High fat diet Carbon Tetrachloride Exposure Steatotic Hepatocytes TAK1 NF-κB Smad2/3 Autophagy Hepatocyte Death Stellate Cell Activation

Fatty liver disease changes the sensitivity to toxin exposure that enhances liver fibrosis High fat diet Chronic Industrial Toxin Exposure Fatty Liver Liver Cirrhosis

Acknowledgement UC San Diego Superfund Research Center Ekihiro Seki MD, PhD (Project5) David A. Brenner MD (Co-leader) Yoon Seok Roh DVM,PhD Shuang Liang PhD Hiroshi Matsushita MD, PhD Sayaka Inokuchi-Shimuzu MD,PhD Ling Yang MD,PhD Bi Zhang Jingyi Song Robert Tukey PhD (Director) Michael Karin PhD (Project 1) Koji Taniguchi MD,PhD XieFeng Wu PhD Mark Ellisman PhD (Core) Mason Mackey